Tvardi Therapeutics (LTS:0HTC) EPS (Basic): £-1.19 (TTM As of Mar. 2026)


What is Tvardi Therapeutics EPS (Basic)?

Tvardi Therapeutics LTS:0HTC 12 EPS (Basic) is £-1.19 as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Tvardi Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was £-0.55. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was £-1.19.

Tvardi Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was £-0.55. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was £-2.31.

Tvardi Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was £-0.55. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -2.31.

During the past 3 years, the average EPS without NRI Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Tvardi Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 25.80% per year. The lowest was 25.80% per year. And the median was 25.80% per year.

Tvardi Therapeutics  (LTS:0HTC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Tvardi Therapeutics EPS (Basic) Related Terms

Tvardi Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics EPS (Basic) Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-6.55 -5.32 -9.03 -1.84

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -2.88 0.38 -0.44 -0.58 -0.55

Tvardi Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Tvardi Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-13.606-0)/7.419
=-1.83

Tvardi Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.103-0)/9.381
=-0.54

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of £-1.19 mean?
Tvardi Therapeutics (LTS:0HTC) has a EPS (Basic) of £-1.19 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' EPS (Basic) too high?
Tvardi Therapeutics' current EPS (Basic) is £-1.19. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' EPS (Basic) compare to PLRZ and BOLD?
Tvardi Therapeutics' EPS (Basic) of £-1.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current EPS (Basic) is £-1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current EPS (Basic) of £-1.19. The current EPS (Basic) is £-1.19. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current EPS (Basic) is £-1.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.